| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Imaradenant (AZD4635; HTL-1071) is a novel, potent, selective, orally bioavailable small molecule inhibitor of the adenosine A2A receptor (A2AR) (Ki = 1.7 nM) with potential anticancer immunomodulatory activity. It binds to human A2AR and exhibits > 30-fold selectivity over other adenosine receptors, making it a promising agent for cancer immunotherapy. By inhibiting A2aR signaling, AZD4635 can improve antitumor immunity and lessen the burden of tumors. In patients with solid cancers, AZD4635 is presently being investigated in a Phase 1 clinical trial both as a single treatment and in conjunction with durvalumab (anti-PD-L1 Ab). Tumors use the microenvironment's extracellular adenosine accumulation as a means of evading immune surveillance.
| Targets |
A2AR ( Ki = 1.7 nM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Enzyme Assay |
It exhibits >30-fold selectivity over other adenosine receptors and binds to human A2AR with a Ki of 1.7 nM.
|
||
| Cell Assay |
Adenosine at concentrations ranging from 0.1 to 10 μM was incubated with CHO cells that were stably expressing human A2AR. The IC50 of AZD4635 for the inhibition of cAMP production was 0.79, 10.0, and 142.9 nM, respectively, in the presence of 0.1, 1, and 10 μM adenosine. AZD4635 was found to reverse suppression and restore IFNγ secretion in cells incubated with 5’-N-ethylcarboxamidoadenosine (NECA), a stable analogue of adenosine, in an ex vivo CD8+ T cell assay.
|
||
| Animal Protocol |
|
||
| References | |||
| Additional Infomation |
Imaradenant is under investigation in clinical trial NCT03381274 (Oleclumab (MEDI9447) Egfrm NSCLC Novel Combination Study).
Imaradenant is an orally bioavailable antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, imaradenant selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression. |
| Molecular Formula |
C15H11CLFN5
|
|
|---|---|---|
| Molecular Weight |
315.73
|
|
| Exact Mass |
315.069
|
|
| Elemental Analysis |
C, 57.06; H, 3.51; Cl, 11.23; F, 6.02; N, 22.18
|
|
| CAS # |
1321514-06-0
|
|
| Related CAS # |
|
|
| PubChem CID |
86676119
|
|
| Appearance |
Solid powder
|
|
| LogP |
3.864
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
22
|
|
| Complexity |
366
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
ClC1=CC(=CC(C)=N1)C1C(C2C=CC(=CC=2)F)=NC(N)=NN=1
|
|
| InChi Key |
NCWQLHHDGDXIJN-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C15H11ClFN5/c1-8-6-10(7-12(16)19-8)14-13(20-15(18)22-21-14)9-2-4-11(17)5-3-9/h2-7H,1H3,(H2,18,20,22)
|
|
| Chemical Name |
6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 5% DMSO + 95% Corn oil: 1.1mg/ml (3.48mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1673 mL | 15.8363 mL | 31.6726 mL | |
| 5 mM | 0.6335 mL | 3.1673 mL | 6.3345 mL | |
| 10 mM | 0.3167 mL | 1.5836 mL | 3.1673 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03381274 | Active Recruiting |
Drug: AZD4635 Drug: Osimertinib |
Carcinoma, Non-Small -Cell Lung |
MedImmune LLC | May 8, 2018 | Phase 1 Phase 2 |
| NCT03980821 | Completed | Drug: AZD4635 | Advanced Solid Malignancies | AstraZeneca | July 4, 2019 | Phase 1 |
| NCT03710434 | Completed | Drug: AZD4635 solid oral formulation - fasted Drug: AZD4635 solid oral formulation - fed |
Healthy Volunteers | AstraZeneca | November 1, 2018 | Phase 1 |
| NCT04495179 | Completed | Drug: AZD4635 Drug: Durvalumab |
Progressive Metastatic Castrate -Resistant Prostate Cancer |
AstraZeneca | August 4, 2020 | Phase 2 |
| NCT04478513 | Completed | Drug: AZD4635 Drug: Fluvoxamine |
Healthy Volunteer/DDI Study | AstraZeneca | July 21, 2020 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
